Gene editing biotech Verve to raise $267M in large IPO

Dive Brief: Verve Therapeutics, a high-profile startup developing a more precise form of gene editing, announced Wednesday it raised nearly $270 million in an initial public offering that will rank as one of the largest in biotech this year.   The company sold just over 14 million shares at $19 apiece through the IPO. Shares will […]